Lina Wang1,2,3, Shiyuan Zhou3, Jiansheng Xie4, Huafang Gao2, Fengyu Wang3, Jiping Zhou3, Yanli Wang3, Haili Wang3. 1. Peking Union Medical College Graduate School, Beijing 100730, China. 2. National Research Institute for Health and Family Planning, Beijing 100081, China. 3. Key Laboratory of Birth defects Prevention, National Health and Family Planning Commission, Zhengzhou 450002, China. 4. Prenatal Diagnosis Center, Shenzhen Maternal and Child Health Hospital, Shenzhen 518040, China.
Abstract
BACKGROUND: Gene mutations of BRCA1 gene play a role in breast cancer. These mutations exist racial differences and can be inherited. The aim of the research is to study the relativity of BRCA1 gene germline mutations with familial breast cancer patients in Henan, China. METHODS: Comprehensive BRCA1 germline mutation analyses were performed through denaturing high-performance liquid chromatography (DHPLC) in a cohort of 59 breast cancer patients and 122 healthy donors with family history of breast cancer. The mutations detected by DHPLC were further validated by Sanger sequencing. RESULTS: About 52.54% (31/59) of familiar breast cancer patients showed BRCA1 germline mutations, which is higher than other previous reports with Chinese patients. However, the mutation rate was only 5.74% (7/122) in healthy donors with family history of breast cancer, and also all these mutations were in BRCA1 of all these mutations detected in both patients and healthy donors, mutation A3780G in BRCA1 gene was reported for the first time. The mutation hotspots were A3113G and A3780G in BRCA1 at least in this cohort of patients in Henan, China. CONCLUSIONS: BRCA1 germline mutations are related most closely to familial breast cancer patients in Henan China.
BACKGROUND: Gene mutations of BRCA1 gene play a role in breast cancer. These mutations exist racial differences and can be inherited. The aim of the research is to study the relativity of BRCA1 gene germline mutations with familial breast cancer patients in Henan, China. METHODS: Comprehensive BRCA1 germline mutation analyses were performed through denaturing high-performance liquid chromatography (DHPLC) in a cohort of 59 breast cancer patients and 122 healthy donors with family history of breast cancer. The mutations detected by DHPLC were further validated by Sanger sequencing. RESULTS: About 52.54% (31/59) of familiar breast cancer patients showed BRCA1 germline mutations, which is higher than other previous reports with Chinese patients. However, the mutation rate was only 5.74% (7/122) in healthy donors with family history of breast cancer, and also all these mutations were in BRCA1 of all these mutations detected in both patients and healthy donors, mutation A3780G in BRCA1 gene was reported for the first time. The mutation hotspots were A3113G and A3780G in BRCA1 at least in this cohort of patients in Henan, China. CONCLUSIONS: BRCA1 germline mutations are related most closely to familial breast cancer patients in Henan China.
Authors: Nasim Mavaddat; Susan Peock; Debra Frost; Steve Ellis; Radka Platte; Elena Fineberg; D Gareth Evans; Louise Izatt; Rosalind A Eeles; Julian Adlard; Rosemarie Davidson; Diana Eccles; Trevor Cole; Jackie Cook; Carole Brewer; Marc Tischkowitz; Fiona Douglas; Shirley Hodgson; Lisa Walker; Mary E Porteous; Patrick J Morrison; Lucy E Side; M John Kennedy; Catherine Houghton; Alan Donaldson; Mark T Rogers; Huw Dorkins; Zosia Miedzybrodzka; Helen Gregory; Jacqueline Eason; Julian Barwell; Emma McCann; Alex Murray; Antonis C Antoniou; Douglas F Easton Journal: J Natl Cancer Inst Date: 2013-04-29 Impact factor: 13.506
Authors: Timothy R Rebbeck; Tara M Friebel; Nandita Mitra; Fei Wan; Stephanie Chen; Irene L Andrulis; Paraskevi Apostolou; Norbert Arnold; Banu K Arun; Daniel Barrowdale; Javier Benitez; Raanan Berger; Pascaline Berthet; Ake Borg; Saundra S Buys; Trinidad Caldes; Jonathan Carter; Jocelyne Chiquette; Kathleen B M Claes; Fergus J Couch; Cezary Cybulski; Mary B Daly; Miguel de la Hoya; Orland Diez; Susan M Domchek; Katherine L Nathanson; Katarzyna Durda; Steve Ellis; D Gareth Evans; Lenka Foretova; Eitan Friedman; Debra Frost; Patricia A Ganz; Judy Garber; Gord Glendon; Andrew K Godwin; Mark H Greene; Jacek Gronwald; Eric Hahnen; Emily Hallberg; Ute Hamann; Thomas V O Hansen; Evgeny N Imyanitov; Claudine Isaacs; Anna Jakubowska; Ramunas Janavicius; Katarzyna Jaworska-Bieniek; Esther M John; Beth Y Karlan; Bella Kaufman; KConFab Investigators; Ava Kwong; Yael Laitman; Christine Lasset; Conxi Lazaro; Jenny Lester; Niklas Loman; Jan Lubinski; Siranoush Manoukian; Gillian Mitchell; Marco Montagna; Susan L Neuhausen; Heli Nevanlinna; Dieter Niederacher; Robert L Nussbaum; Kenneth Offit; Edith Olah; Olufunmilayo I Olopade; Sue Kyung Park; Marion Piedmonte; Paolo Radice; Christine Rappaport-Fuerhauser; Matti A Rookus; Caroline Seynaeve; Jacques Simard; Christian F Singer; Penny Soucy; Melissa Southey; Dominique Stoppa-Lyonnet; Grzegorz Sukiennicki; Csilla I Szabo; Mariella Tancredi; Manuel R Teixeira; Soo-Hwang Teo; Mary Beth Terry; Mads Thomassen; Laima Tihomirova; Marc Tischkowitz; Amanda Ewart Toland; Aleksandra Toloczko-Grabarek; Nadine Tung; Elizabeth J van Rensburg; Danylo Villano; Shan Wang-Gohrke; Barbara Wappenschmidt; Jeffrey N Weitzel; Jamal Zidan; Kristin K Zorn; Lesley McGuffog; Douglas Easton; Georgia Chenevix-Trench; Antonis C Antoniou; Susan J Ramus Journal: Breast Cancer Res Date: 2016-11-11 Impact factor: 6.466